SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
|
|
- Ashlynn Lloyd
- 5 years ago
- Views:
Transcription
1 Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D Nexus Center Drive San Diego, CA US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN TYPE COLLECTED DATE G PGTST-NTAB SALIVA Feb 19, 2016 RECEIVED DATE Feb 22, 2016 Drug Class Drug Preferential Use Use As Directed ay Have Significant Limitations ay Cause Serious Adverse Events Citalopram Escitalopram Fluoxetine SSRIs Fluvoxamine Paroxetine Sertraline Vilazodone Amitriptyline Clomipramine Desipramine TCAs Doxepin Imipramine Nortriptyline Protriptyline Trimipramine Bupropion Buspirone Duloxetine Levomilnacipran Other Antidepressants irtazapine Nefazodone Trazodone Venlafaxine Vortioxetine Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 1 of 11
2 ENTAL HEALTH DNA INSIGHT Drug Class Drug Preferential Use Use As Directed ay Have Significant Limitations ay Cause Serious Adverse Events Aripiprazole Asenapine Clozapine Iloperidone Atypical Antipsychotics Lurasidone Olanzapine Paliperidone Quetiapine Risperidone Ziprasidone Haloperidol Perphenazine Typical Antipsychotics Pimozide Thioridazine Zuclopenthixol Carbamazepine Divalproex ood Stabilizers Lamotrigine Oxcarbazepine Phenytoin Valproic acid Norepinephrine Reuptake Inhibitor Atomoxetine Alprazolam Benzodiazepines Clobazam Diazepam Dextromethorphan and Quinidine Others Galantamine odafinil Tetrabenazine Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 2 of 11
3 ENTAL HEALTH DNA INSIGHT Drug Class Drug Comments SSRIs Citalopram ay Cause Serious Adverse Events Patient's genotype is associated with greatly reduced metabolism of citalopram compared to extensive metabolizers, which may increase the risk of adverse effects. Alternative medications that are not primarily metabolized by the CYP2C19 enzyme should be considered. Reduction of the starting dose is recommended if treatment of citalopram is warranted. The SLC6A4 alleles found in this patient cannot determine the benefit or limitation of the use of SSRI antidepressants. Escitalopram Sertraline Patient's genotype is associated with greatly reduced metabolism of escitalopram compared to extensive metabolizers, which may increase the risk of adverse effects. Alternative medications that are not primarily metabolized by the CYP2C19 enzyme should be considered. Reduction of the starting dose is recommended if treatment of escitalopram is warranted. Patient's genotype is associated with greatly reduced metabolism of sertraline compared to extensive metabolizers, which may increase the risk of adverse effects. Alternative medications that are not primarily metabolized by the CYP2C19 enzyme should be considered. Reduction of the starting dose is recommended if treatment of sertraline is warranted. Other Antidepressants Venlafaxine Patient's genotype is associated with increased plasma concentrations of venlafaxine at standard doses, which may increase risk of adverse effects. Consider alternative medications that are not primarily metabolized by the CYP2D6 enzyme. The SLC6A4 alleles found in this patient cannot determine the benefit or limitation of the use of SSRI antidepressants. Atypical Antipsychotics Risperidone Patient's genotype is associated with an increased plasma risperidone:9-oh-risperidone ratio, which may increase the risk of adverse effects. Consider an alternative drug or monitor patient for adverse events and adjust dosage accordingly. Typical Antipsychotics Thioridazine Patient's genotype is associated with decreased CYP2D6 enzyme activity. The CYP2D6 enzyme contributes to the clearance of cardiotoxic thioridazine and is inhibited by the drug. Thioridazine is contraindicated in patients with reduced CYP2D6 enzyme activity. Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 3 of 11
4 ENTAL HEALTH DNA INSIGHT Drug Class Drug Comments ood Stabilizers Carbamazepine ay Cause Serious Adverse Events (Continued) Patient's risk of developing carbamazepine hypersensitivity cannot be determined from the genotype results. It cannot be determined whether or not this patient has the HLA- B*1502 allele that is associated with serious skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, if treated with carbamazepine. The genetic test for this condition is most applicable to patients of Han Chinese descent. If clinically indicated, patients of Asian descent, including Han Chinese who receive an "Unknown" outcome, could be advised to undergo HLA sequencing to assess their risk of carbamazepine hypersensitivity. Other HLA alleles have been shown to be associated with carbamazepine hypersensitivity in people of Caucasian and Japanese descent, in whom HLA-B*1502 is largely absent. Lamotrigine Oxcarbazepine Phenytoin Patient's risk of developing severe cutaneous adverse reactions to lamotrigine cannot be determined from the genotype results. It cannot be determined whether or not this patient has the HLA-B*1502 allele that has been reported in patients who developed serious skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, when treated with lamotrigine. The genetic test for this condition is most applicable to patients of Han Chinese descent. If clinically indicated, patients of Asian descent, including Han Chinese who receive an "Unknown" outcome, could be advised to undergo HLA sequencing to assess their risk of lamotrigine hypersensitivity. Other HLA alleles have been shown to be associated with lamotrigine hypersensitivity in people of Caucasian and Japanese descent, in whom HLA-B*1502 is largely absent. Patient's risk of developing oxcarbazepine hypersensitivity cannot be determined from the genotype results. It cannot be determined whether or not this patient has the HLA-B*1502 allele that is associated with serious skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, if treated with oxcarbazepine. The genetic test for this condition is most applicable to patients of Han Chinese descent. If clinically indicated, patients of Asian descent, including Han Chinese who receive an "Unknown" outcome, could be advised to undergo HLA sequencing to assess their risk of oxcarbazepine hypersensitivity. Other risk factors may contribute to oxcarbazepine hypersensitivity in people of Caucasian and Japanese descent, in whom HLA-B*1502 is largely absent. Patient's risk of developing phenytoin hypersensitivity cannot be determined from the genotype results. It cannot be determined whether or not this patient has the HLA-B*1502 allele, which is associated with serious skin reactions, such as Stevens-Johnson syndrome or toxic epidermal Necrolysis (SJS/TEN), when treated with phenytoin. This genetic test is most applicable to patients of Han Chinese descent. If clinically indicated, patients of Asian descent, including Han Chinese who receive an Unknown outcome, may be advised to undergo HLA sequencing to assess their risk of phenytoin hypersensitivity. There are insufficient data to associate this allele with phenytoin hypersensitivity in other ethnicities. This patient's genotype is associated with low CYP2C9 enzyme activity; therefore, the patient may have increased plasma concentrations of phenytoin compared to most patients treated with the same dose. Some studies report an association between this patient's genotype and increased risk of phenytoin toxicity. Symptoms of toxicity include dizziness, nystagmus, ataxia and mental confusion, among others. A reduced dose, monitoring of serum phenytoin concentrations and/or alertness for signs of toxicity could be considered. Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 4 of 11
5 ENTAL HEALTH DNA INSIGHT Drug Class Drug Comments SSRIs Fluvoxamine ay Have Significant Limitations The SLC6A4 alleles found in this patient cannot determine the benefit or limitation of the use of SSRI antidepressants. Patient's genotype is associated with reduced metabolism of fluvoxamine compared to extensive metabolizers, which may increase the risk of adverse effects. Reduction of the starting dose is recommended. There are no specific recommendations on dose adjustments. Paroxetine Patient's genotype is associated with reduced metabolism of paroxetine compared to extensive metabolizers, which may increase the risk of adverse effects. Reduction of the starting dose is recommended. There are no specific recommendations on dose adjustments. TCAs Other Antidepressants Atypical Antipsychotics Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Trimipramine Duloxetine irtazapine Vortioxetine Aripiprazole Iloperidone The SLC6A4 alleles found in this patient cannot determine the benefit or limitation of the use of SSRI antidepressants. Patient's genotype is associated with greatly reduced metabolism of TCAs compared to extensive metabolizers, which may increase the risk of adverse effects. edications other than TCAs should be considered. Therapeutic drug monitoring is recommended to guide dose adjustments if tricyclic treatment is warranted. Patient's genotype is associated with greatly reduced metabolism of TCAs compared to extensive metabolizers, which may increase the risk of adverse effects. Reduction of the starting dose and the use of therapeutic drug monitoring are recommended. Patient's genotype is associated with greatly reduced metabolism of TCAs compared to extensive metabolizers, which may increase the risk of adverse effects. edications other than TCAs should be considered. Therapeutic drug monitoring is recommended to guide dose adjustments if tricyclic treatment is warranted. Patient's genotype is associated with greatly reduced metabolism of TCAs compared to extensive metabolizers, which may increase the risk of adverse effects. Reduction of the starting dose and the use of therapeutic drug monitoring are recommended. Patient's genotype is associated with greatly reduced metabolism of TCAs compared to extensive metabolizers, which may increase the risk of adverse effects. edications other than TCAs should be considered. Therapeutic drug monitoring is recommended to guide dose adjustments if tricyclic treatment is warranted. Patient may have increased plasma concentrations of duloxetine at standard doses. Patient may have increased plasma concentrations of mirtazapine; though it is unclear if increased plasma concentrations of mirtazapine influences therapeutic benefits or the risk of adverse effects. Patient's genotype is associated with decreased oral clearance of vortioxetine compared to CYP2D6 extensive metabolizers. Due to the lack of clinical evidence, there are no specific recommendations on dose adjustment of vortioxetine. Patient's genotype is associated with increased plasma concentrations of aripiprazole at standard doses. Patient may have increased plasma concentrations of iloperidone and its active metabolite. Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 5 of 11
6 ENTAL HEALTH DNA INSIGHT Drug Class Drug Comments Typical Antipsychotics Haloperidol ay Have Significant Limitations (Continued) Patient's genotype is consistent with decreased CYP2D6 activity, and the patient may have increased plasma concentrations of a haloperidol metabolite known as reduced haloperidol. Accumulation of haloperidol and reduced haloperidol in the blood are associated with increased risk of adverse effects. Norepinephrine Reuptake Inhibitor Benzodiazepines Perphenazine Zuclopenthixol Atomoxetine Clobazam Diazepam Patient's genotype is associated with increased plasma concentrations of perphenazine, which may increase the risk of adverse effects. Patient may have increased plasma concentrations of zuclopenthixol, which may increase the risk of adverse effects. Consider reducing the dose by 25% or consider alternative medications. Patient's genotype is associated with increased plasma concentrations and slower elimination of atomoxetine. Due to the lack of clinical evidence, there are no specific recommendations on dose adjustment of atomoxetine. Patient's genotype is associated with increased plasma concentrations of a clobazam's active metabolite, N-desmethylclobazam, compared to CYP2C19 extensive metabolizers. Based on the FDA-approved drug label, clobazam dosage may need to be adjusted. Patient's genotype is associated with increased plasma concentrations and slower clearance of diazepam compared to CYP2C19 extensive metabolizers. Due to the lack of clinical evidence, there are no specific recommendations on dose adjustment of diazepam. Drug Class Drug Comments Atypical Antipsychotics Asenapine Preferential Use asenapine. Clozapine Lurasidone Olanzapine Paliperidone Quetiapine Ziprasidone clozapine. lurasidone. olanzapine. paliperidone. quetiapine. ziprasidone. Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 6 of 11
7 ENTAL HEALTH DNA INSIGHT Drug Class Drug Comments SSRIs Fluoxetine Use As Directed The SLC6A4 alleles found in this patient cannot determine the benefit or limitation of the use of SSRI antidepressants. Vilazodone The most recent label for this drug should be consulted for up-to-date dosing guidelines TCAs Protriptyline The most recent label for this drug should be consulted for up-to-date dosing guidelines Other Antidepressants Bupropion Buspirone Levomilnacipran Nefazodone Trazodone The most recent label for this drug should be consulted for up-to-date dosing guidelines Typical Antipsychotics Pimozide The most recent label for this drug should be consulted for up-to-date dosing guidelines ood Stabilizers Divalproex Valproic acid The most recent label for this drug should be consulted for up-to-date dosing guidelines Benzodiazepines Alprazolam The most recent label for this drug should be consulted for up-to-date dosing guidelines Others Dextromethorphan and Quinidine Galantamine odafinil Tetrabenazine The most recent label for this drug should be consulted for up-to-date dosing guidelines Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 7 of 11
8 ENTAL HEALTH DNA INSIGHT GENOTYPE/HAPLOTYPE DETAIL PHARACOGENETICS This section lists the genetic markers that were tested. Results are organized by gene. Each gene has up to three sections, which may include a "etabolizer Status" section, a "Genetic Result" section and an associated table with three columns. "etabolizer Status" indicates the patient's predicted metabolizer status. "Genetic Result" indicates the haplotype, genotype or presence of a mutation. A genetic result that contains ND indicates that a haplotype could not be determined. Unable To Report indicates that no result can be provided. In the tables, results are organized by gene in three columns: 1. Gene/Locus refers to the gene or intergenic region where the marker is located. 2. arker refers to the unique identifier of the tested marker. 3. Genotype refers to the combination of nucleotides at a particular marker. The letter(s) on each side of the slash refer(s) to the two copies of the patient s DNA. "Del" indicates a deletion of the nucleotide(s) in the patient's DNA. A genotype of - - indicates that a result could not be obtained. CYP1A2 CYP1A2 rs A/C CYP2B6 etabolizer Status: Extensive etabolizer Genetic Result: CYP2B6 *1/*4 CYP2B6 rs A/G CYP2B6 rs C/C CYP2B6 rs G/G CYP2B6 rs C/C CYP2B6 rs A/A CYP2C19 etabolizer Status: Poor etabolizer Genetic Result: CYP2C19 *2/*8 CYP2C19 rs G/A CYP2C19 rs G/G CYP2C19 rs C/C CYP2C19 rs A/A CYP2C19 rs T/C CYP2C19 rs C/C CYP2C19 rs G/G CYP2C19 rs T/T CYP2C9 etabolizer Status: Intermediate etabolizer Genetic Result: CYP2C9 *1/*3 CYP2C9 rs A/C CYP2C9 rs C/C CYP2C9 rs A/A CYP2D6 etabolizer Status: Intermediate etabolizer Genetic Result: CYP2D6 *4/*10 CYP2D6 rs16947 C/C CYP2D6 rs G/G CYP2D6 rs T/T CYP2D6 rs C/C CYP2D6 rs G/A CYP2D6 rs T/T CYP2D6 rs AAG/AAG CYP2D6 rs G/G CYP2D6 rs C/C CYP2D6 rs C/C CYP2D6 rs A/A CYP2D6 rs C/C CYP2D6 rs G/G CYP2D6 rs A/A CYP2D6 rs C/C CYP2D6 rs T/T CYP3A4 CYP3A4 rs A/A CYP3A4 rs C/C CYP3A4 rs C/C CYP3A4 rs A/A CYP3A4 rs A/A CYP3A4 rs C/C CYP3A5 etabolizer Status: Expressor Genetic Result: CYP3A5 *1/*1 CYP3A5 rs T/T DRD2 DRD2 rs C/del HLA-A Genetic Result: HLA-A x/x HLA Region rs A/A HLA-B Genetic Result: HLA-B x/x or *1502/x HLA Region rs C/T HLA Region rs G/C Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 8 of 11
9 ENTAL HEALTH DNA INSIGHT HTR2A HTR2A rs G/G HTR2A HTR2A rs6311 A/G HTR2C HTR2C rs G/G HTR2C rs G/A POLG POLG rs G/G POLG rs G/G POLG rs G/G SLC6A4 Genetic Result: Unknown SLC6A4 Haplotype SLC6A4 5-HTTLPR S/L SLC6A4 rs25531 A/G UGT1A4 UGT1A4 rs A/A Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 9 of 11
10 ENTAL HEALTH DNA INSIGHT TEST ETHODOLOGY Genotyping by PCR-based enrichment and next-generation sequencing or by array-based evaluation of multiple molecular probes. DISCLAIER This test was developed and its performance characteristics determined by Pathway Genomics Corporation. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. If you have any questions about this report or wish to speak with one of Pathway Genomics' genetic counselors, please call (877) RISKS AND LIITATIONS Risk of Laboratory Technical Problems or Laboratory Error The certified testing laboratory has standard and effective procedures in place to protect against technical and operational problems. However, such problems may still occur. The testing laboratory receives samples collected by patients and physicians. Problems in shipping to the laboratory or sample handling can occur, including but not limited to damage to the specimen or related paperwork, mislabeling, and loss or delay of receipt of the specimen. Laboratory problems can occur that might lead to inability to obtain results. Examples include, but are not limited to, sample mislabeling, DNA contamination, un-interpretable results, and human and/or testing system errors. In such cases, the testing laboratory may need to request a new sample. However, upon re-testing, results may still not be obtainable. As with all medical laboratory testing, there is a small chance that the laboratory could report inaccurate information. For example, the laboratory could report that a given genotype is present when in fact it is not. Any kind of laboratory error may lead to incorrect decisions regarding medical treatment and/or diet and fitness recommendations. If a laboratory error has occurred or is suspected, a health care professional may wish to pursue further evaluation and/or other testing. Further testing may be pursued to verify any results for any reason. Limitations The purpose of this test is to provide information about how a tested individual s genes may affect carrier status for some inherited diseases, responses to some drugs, risk for specific common health conditions, and/or selected diet, nutrition and/or exercise responses, as well as to learn more about the tested individual s ancient ancestry, depending upon the specific genetic testing that is ordered by the health care professional. Tested individuals should not make any changes to any medical care (including but not limited to changes to dosage or frequency of medications, diet and exercise regimens, or pregnancy planning) based on genetic testing results without consulting a health care professional. The science behind the significance or interpretation of certain testing results continues to evolve. Although great strides have been made to advance the potential usefulness of genetic testing, there is still much to be discovered. Genetic testing is based upon information, developments and testing techniques that are known today. Future research may reveal changes in the interpretation of previously obtained genetic testing results. For example, any genetic test is limited by the variants being tested. The interpretation of the significance of some variants may change as more research is done about them. Some variants that are associated with disease, drug response, or diet, nutrition and exercise response may not be tested; possibly these variants have not yet been identified in genetic studies. any of the conditions and drug responses that are tested are dependent on genetic factors as well as nongenetic factors such as age, personal health and family health history, diet, and ethnicity. As such, an individual may not exhibit the specific drug response, disease, or diet, nutrition and exercise response consistent with the genetic test results. Another limitation for some conditions, particularly in the areas of diet and exercise, is that genetic associations have been studied and observed in Caucasian populations only, and in some cases only in one gender. In this case, the interpretations and recommendations are made in the context of Caucasian studies, but the results may or may not be relevant to tested individuals who are of non-caucasian or mixed ethnicities or the non-studied gender. If patient ethnicity is not disclosed in the test requisition form the ethnicity field in the report will read as "Ethnicity: Not Reported". Such reports will be defaulted to phenotype list displayed for Caucasian ethnicity. Based on test results and other medical knowledge of the tested individual, health care professionals might consider additional independent testing, or consult another health care professional or genetic counselor. Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 10 of 11
11 ENTAL HEALTH DNA INSIGHT RESULT STATUS DEFINITIONS Amended Test results and/or patient information that have been revised in a way that does not impact the clinical significance of the result(s) and/or patient diagnosis, treatment or management. Corrected Test results and/or patient information that have been revised in a way that may impact the clinical significance of the result(s) and/or patient diagnosis, treatment or management. Final Test results that are available at the time of report issue or have been revised from pending status to final status. Pending Test results that are not available at the time of report issue. All pending results will be specified in the report. Laboratory Director: Nilesh Dharajiya,.D. CLIA Number: 05D Nexus Center Drive, San Diego, CA PAGE 11 of 11
12
SAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationPAIN MEDICATION DNA INSIGHT
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya, M.D. PAIN MEDICATION DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROESSIONAL Nilesh
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationPharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationPSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX
A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationHEDIS BEHAVIORAL HEALTH RESOURCE GUIDE
HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information
More informationYour Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane,
1 Jane Doe DOB: 1985-01-05 Sample ID: CL-4194-DM Hello Jane, Thank you for ordering your Kailos test for antidepressants. Kailos Genetics is committed to making gene-based healthcare available to YOU.
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationNew Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
More informationETHNICITY AND PSYCHOTROPIC RESPONSE
Ethnic Differences in Drug Metabolism ETHNICITY AND PSYCHOTROPIC RESPONSE Bridging Cultures: Improving Evaluation & Treatment of Cognitive 8 March 28 Keh-Ming Lin, M.D., M.P.H. Professor Emeritus of Psychiatry,
More informationDisclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015
49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University
More informationPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
(2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
More informationPrescriber s Guide. Stahl s Essential Psychopharmacology
Stahl s Essential Psychopharmacology Prescriber s Guide FIFTH EDITION With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationPsychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA
Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get
More informationCardiovascular Health. Heart Disease / Atrial Fibrillation. Hypertension
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationEligible Beneficiaries
Therapeutic Class: Behavioral Health Medications for Adults Clinical Edit Number Long Description 4110 (May change) Quantity limit edit that is applied to atypical antipsychotics for claims identified
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationPharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationOverview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials
SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time?
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationGenetic Testing Patient Guide
Genetic Testing Patient Guide Over the last decade, pharmacogenetics has become increasingly significant to clinical practice. Psychiatric patients, in particular, may benefit from pharmacogenetic testing
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationPsychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing
Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing CMS NEWEST GUIDELINES CMS will push nursing homes to reduce their use
More informationPharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study
For reprint orders, please contact: reprints@futuremedicine.com Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study Theresa R Tonozzi
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationSteps for Initiating Electroconvulsive Therapy Treatment
Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral
More informationRetrospective Drug Use Review for the Use of Psychotropic Medications in Children
Retrospective Drug Use Review for the Use of Psychotropic Medications in Children Recommendations Send providers an annual request for additional clinical data for children receiving any of the following
More informationInduction by Antiepileptic Drugs: An Update for Clinicians Jose de Leon, MD ( )
Induction by Antiepileptic Drugs: An Update for Clinicians Jose de Leon, MD (11-21-15) Conflicts of Interest: About the Field 1) Dr. de Leon is firmly convinced that the literature is contaminated by false
More informationThe clinical response to the same dose
Making sense of CYP2D6 and CYP1A2 genotype vs phenotype O. Greg Deardorff, PharmD, BCPP, Victoria Jenne, PharmD, MPH, BCPS, and Lauren Leonard, PharmD The clinical response to the same dose of a drug may
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationCanterbury District Health Board Endocrine Test Centre Protocols. Date Signature Next review Sign when read
0855 Prolactin Series test ASY-855.1: Associated documents Prolactin Series Test Patient information sheet Prolactin series sample request form 0 ASY-855.2: Distribution of Documents Copy No Number Location
More informationCONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationPOSTPARTUM MOOD DISORDERS Identification and Treatment Cheryl Carroll CNM, PMHNP Psych Retreat Greensboro, NC
POSTPARTUM MOOD DISORDERS Identification and Treatment Cheryl Carroll CNM, PMHNP 2017 Psych Retreat Greensboro, NC Postpartum Depression DSM 5 Major Depressive Disorder Diagnostic Criteria specifer: with
More informationTherapeutic Drugs Monitoring TDM 2018 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationTherapeutic Drugs Monitoring TDM 2016 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationWeighty Issues with Psychotropic Use in Adolescents and Young Adults
Weighty Issues with Psychotropic Use in Adolescents and Young Adults Sheila Botts, PharmD, BCPP, FCCP Chief, Clinical Pharmacy Research & Academic Affairs Kristen N. Gardner, PharmD Clinical Pharmacy Specialist
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationPolicy Evaluation: Low Dose Quetiapine Safety Edit
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More information2015 Update on Psychotropics
2015 Update on Psychotropics Jeffrey T. Apter, M.D. August 2015 Princeton Medical Institute 256 Bunn Drive, Suite 6, Princeton NJ (609) 921-6050 Learning Objectives Upon completion of this session, participants
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationStep Therapy Medications
Step Therapy Medications Step Therapy Group APTIOM Step-2: APTIOM 200 MG TABLET or APTIOM 400 MG TABLET or APTIOM 600 MG TABLET or APTIOM 800 MG TABLET Step 1 Drug(s): Oxcarbazepine immediate-release,
More information7-8 September 2016 Sheraton Hotel & Towers Ho Chi Minh City, Vietnam
7-8 September 2016 Sheraton Hotel & Towers Ho Chi Minh City, Vietnam www.hospitalmanagementasia.com Implementing pharmacogenomics into the clinical space to improve efficacy and safety of medication therapies
More informationThe use of pharmacogenetic testing to help drive
Pharmacogenetic testing in children: What to test and how to use it Pediatric-specific evidence is limited, but testing can inform treatment, improve outcomes Laura B. Ramsey, PhD Assistant Professor Divisions
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationOhana Community Care Services (CCS) Comprehensive Preferred Drug List (List of Covered Drugs)
2015 Ohana Community Care Services (CCS) Comprehensive referred Drug List (List of Covered Drugs) Ohana Health lan 00 lease read: This document contains information about the drugs we cover in this plan.
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationHappy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?
Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms
More informationIndex. E Elderly and dementia, 2 Epilepsy, 59 Escitalopram, 51, 87 Estazolam, 101 Extrapyramidal symptoms (EPS), 18
A Abilify, 143 Absolute neutrophil count (ANC), 29 Acetylcholine (Ach), 14, 15 ACTivities of daily living and cognition (ACTION) study, 167 AD Anti-inflammatory Prevention Trial (ADAPT) study, 156 Adverse
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationDuragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationMedically Accepted Indications for Pediatric Use of Psychotropic Medications by
Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:
More informationHEDIS Resource Guide Behavioral Health
HEDIS Resource Guide Behavioral Health NA8PROGDE04232E_0000 What s Inside 1 What is HEDIS? 2 HEDIS Reference Guide for Behavioral Health 14 Behavioral Health HEDIS Measures What Is HEDIS? The Healthcare
More informationPharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)
Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient
More informationMO Medicaid Foster Care Drugs FY10-FY14
MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri
More informationWelcome and thank you for choosing University of Florida Physicians!
DEPARTMENT OF PSYCHIATRY Tuesday, Division of March Child and 14, Adolescent 2017 Psychiatry 8491 NW 39 th Ave. Gainesville, FL 32606 Phone: 352-265-4357 Fax: 352-627-4163 Welcome and thank you for choosing
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationDealing with a Mental Health Crisis
Dealing with a Mental Health Crisis Information and Resources for First Responders P... PROFESSIONAL WHAT NAMI DOES NAMI Minnesota is a statewide 501(c)(3) grassroots nonprofit organization dedicated to
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationORDERING HEALTHCARE PROFESSIONAL. Nilesh Dharajiya, M.D Nexus Center Drive San Diego, CA US
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya, M.D. PATHWAY IT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROESSIONAL Nilesh Dharajiya, M.D. 4755
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationBefore you try another medication, try asking your DNA
Before you try another medication, try asking your DNA It s not you, it s your genetics If you re having trouble finding a medication that works for you, don t give up hope. Here s the thing we all respond
More informationProfessor David Castle. Ms. Nga Tran. St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065
ARABIIC Professor David Castle Ms. Nga Tran St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 (03) 9288 4147 (03) 9288 4751 Psychiatric Medication Information / Arabic 1 Psychiatric
More informationAntidepressant Medication Mgmt
August 2012 MHSPHP Background The Military Health System Population Health Portal (MHSPHP) methodology is based on 2012 Healthcare Effectiveness Data and Information Set (HEDIS ) criteria. These are a
More informationSupplementary Online Content
Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published
More informationABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
More informationMental Health Medications. National Institute of Mental Health. U.S. Department of HealtH and HUman ServiceS National Institutes of Health
Mental Health Medications National Institute of Mental Health U.S. Department of HealtH and HUman ServiceS National Institutes of Health Contents Mental Health Medications...1 What are psychiatric medications?...1
More information